CAS 571190-30-2

Palbociclib

Descrizione:

Palbociclib è un farmaco orale classificato come inibitore selettivo delle chinasi dipendenti dalle cicline 4 e 6 (CDK4/6), utilizzato principalmente nel trattamento del cancro al seno positivo ai recettori ormonali e negativo per il recettore 2 del fattore di crescita epidermico umano. La sua formula chimica è C24H29N5O2 e presenta una struttura complessa che include un anello di piridazina, cruciale per la sua attività biologica. Palbociclib agisce interrompendo il ciclo cellulare, inibendo specificamente la transizione dalla fase G1 alla fase S, prevenendo così la proliferazione delle cellule tumorali. La sostanza viene tipicamente somministrata in combinazione con inibitori dell'aromatasi o antagonisti del recettore degli estrogeni per migliorare l'efficacia terapeutica. Palbociclib è caratterizzato dalla sua solubilità moderata nei solventi organici e dalla relativa bassa solubilità in acqua, il che può influenzare la sua biodisponibilità. La sua farmacocinetica indica un significativo metabolismo di primo passaggio, principalmente da parte del fegato, e ha una emivita che supporta la somministrazione una volta al giorno. Come per molte terapie mirate, è essenziale monitorare gli effetti collaterali come la neutropenia durante il trattamento.

Formula: C₂₄H₂₉N₇O₂

InChI: InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

InChI key: InChIKey=AHJRHEGDXFFMBM-UHFFFAOYSA-N

SMILES: O=C1N(C=2C(C(C)=C1C(C)=O)=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N2)C5CCCC5

Sinonimi:

• 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)pyrido[2,3-d]pyridin-7(8H)-one
• 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one
• 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
• Ibrance
• Otava-Bb 1115529
• Palbociclib
• Palbociclib base
• Palbocyclib
• Pd 332991
• Pd 991
• Pd-0332991
• Pd0332991

Palbociclib

CAS: 571190-30-2

Palbociclib

Purezza: ≥98%

Peso molecolare: 447.53g/mol

Ref: 54-BUP14421

Palbociclib

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Colore e forma: Yellow Solid

Peso molecolare: 447.54

Ref: 4Z-P-196001

Palbociclib

CAS: 571190-30-2

Colore e forma: Neat

Ref: 86-MM3729.00

Palbociclib

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Purezza: >97.0%(T)(HPLC)

Colore e forma: White to Yellow to Yellow green powder to crystal

Peso molecolare: 447.54

Ref: 3B-P3315

Palbociclib

CAS: 571190-30-2

Palbociclib is an oral CDK4/6 inhibitor, halts Rb phosphorylation, arrests cell cycle, and curbs tumor growth.

Formula: C₂₄H₂₉N₇O₂

Purezza: 98% - 99.9%

Colore e forma: Solid

Peso molecolare: 447.53

Ref: TM-T1785

Palbociclib

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Purezza: (TLC) ≥ 98.0%

Colore e forma: Yellow powder

Peso molecolare: 447.53

Ref: 7W-GX0330

Palbociclib

CAS: 571190-30-2

Applications Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009);

Formula: C₂₄H₂₉N₇O₂

Colore e forma: Neat

Peso molecolare: 447.53

Ref: TR-P139900

Palbociclib Sulfate Sodium Salt

Prodotto controllato

CAS: 571190-30-2

Applications Palbociclib Sulfate is a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₂₄H₂₈N₇NaO₅S

Colore e forma: Neat

Peso molecolare: 549.58

Ref: TR-P139905

Palbociclib-d4

Prodotto controllato

CAS: 571190-30-2

Applications Palbociclib-d4 is an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₂₄H₂₅D₄N₇O₂

Colore e forma: Light Yellow

Peso molecolare: 451.56

Ref: TR-P139901

Palbociclib - Bio-X ™

CAS: 571190-30-2

This product is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Formula: C₂₄H₂₉N₇O₂

Purezza: Min. 95%

Colore e forma: Powder

Peso molecolare: 447.53 g/mol

Ref: 3D-BP166224

Palbociclib

CAS: 571190-30-2

Selective and potent inhibitor of cyclin-dependent kinases CDK4 and CDK6. It blocks cell cycle progression from phase G1 into S by inhibiting CDK4/6-dependent retinoblastoma (RB) phosphorylation. It has been used for the treatment of HER2 negative, estrogen receptor (ER) positive metastatic breast cancer.

Formula: C₂₄H₂₉N₇O₂

Purezza: Min. 95%

Colore e forma: Powder

Peso molecolare: 447.53 g/mol

Ref: 3D-FA65120

Palbociclib-d4 Hydrochloride

Prodotto controllato

CAS: 571190-30-2

Applications Palbociclib-d4 Hydrochloride is an intermediate in synthesizing Palbociclib-d4 (P139901), an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₂₅H₂₇D₄N₇O₂·HCl

Colore e forma: Neat

Peso molecolare: 502.04

Ref: TR-P139937

Palbociclib N-Beta-D-Glucuronide Sodium Salt (Technical Grade, ~65%)

Prodotto controllato

CAS: 571190-30-2

Applications Palbociclib N-β-D-Glucuronide is a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₃₀H₃₆N₇NaO₈

Purezza: ~65%

Colore e forma: Neat

Peso molecolare: 645.64

Ref: TR-P139910

Palbociclib

CAS: 571190-30-2

Purezza: 95%

Colore e forma: Solid

Peso molecolare: 447.5429993

Ref: 10-F794410

Maillard Product

Prodotto controllato

CAS: 571190-30-2

Formula: C₃₆H₄₉N₇O₁₂

Colore e forma: Neat

Peso molecolare: 771.814

Ref: TR-M411860

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)pyrido[2,3-d]pyridin-7(8H)-one

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Colore e forma: Solid

Peso molecolare: 447.5328

Ref: IN-DA00367H